SR9009 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
== Prognosis == Androgenic alopecia is typically experienced as a "moderately stressful condition that diminishes body image satisfaction". However, although most men regard baldness as an unwanted and distressing experience, they usually can cope and retain integrity of personality. Although baldness is not as common in women as in men, the psychological effects of hair loss tend to be much greater. Typically, the frontal hairline is preserved, but the density of hair is decreased in all areas of the scalp. Previously, it was believed to be caused by testosterone, just as in male baldness, but most women who lose hair have normal testosterone levels.
The oxidation step uses oxidised nicotinamide adenine dinucleotide as a cofactor and the enzyme also requires zinc. It belongs to the family of oxidoreductases, specifically those acting on single donors with O2 as oxidant and incorporation of two atoms of oxygen into the substrate (oxygenases). The oxygen incorporated need not be derived from O2. The systematic name of this enzyme class is 3,4-dihydroxy-L-phenylalanine:oxygen 4,5-oxidoreductase (recyclizing). It participates in tyrosine metabolism.
Dislocations or subluxations (that is, partial dislocations) Sprains, tendinitis, or bursitis from activities. However, a 2018 study reports that while hypermobile individuals are more likely to suffer dislocations doing sports than non-hypermobile individuals, they are less likely to suffer muscle and tendon sprains. The overall chances of sports injury are not significantly different. Joint pain Back pain Joints that make clicking noises Chance of nerve compression disorders in the joints (such as carpal tunnel syndrome) "Growing pains" (as described in children in late afternoon or night)
In sensory neurons, action potentials result from an external stimulus. However, some excitable cells require no such stimulus to fire: They spontaneously depolarize their axon hillock and fire action potentials at a regular rate, like an internal clock. The voltage traces of such cells are known as pacemaker potentials. The cardiac pacemaker cells of the sinoatrial node in the heart provide a good example. Although such pacemaker potentials have a natural rhythm, it can be adjusted by external stimuli; for instance, heart rate can be altered by pharmaceuticals as well as signals from the sympathetic and parasympathetic nerves. The external stimuli do not cause the cell's repetitive firing, but merely alter its timing. In some cases, the regulation of frequency can be more complex, leading to patterns of action potentials, such as bursting.
Sources: en.wikipedia.org
==== Improved reproducibility ==== Overcoming issues of reproducibility has become a topic of growing concern across scientific disciplines. Reproducibility can be especially salient when multiple iterations of the same experimental protocol need to be repeated. Using liquid handling robots that can minimize volume loss between experimental steps are often used to reduce error rates and improve reproducibility. An automated DMF system for CRISPR-Cas9 genome editing was described by Sinha et al, and was used to culture and genetically modify H1299 lung cancer cells. The authors noted that no variation in knockout efficiencies across loci was observed when cells were cultured on the DMF device, whereas cells cultured in well-plates showed variability in upstream loci knockout efficiencies. This reduction in variability was attributed to culturing on a DMF device being more homogenous and reproducible compared with well plate methods.
{\displaystyle {\begin{aligned}&{\frac {dS}{d\tau }}=-SI-b(\tau )S,\\[6pt]&{\frac {dI}{d\tau }}=SI-[k(\tau )+q(\tau )]I,\\[6pt]&{\frac {dR}{d\tau }}=k(\tau )I,\\[6pt]&{\frac {dV}{d\tau }}=b(\tau )S,\\[6pt]&{\frac {dD}{d\tau }}=q(\tau )S\end{aligned}}}
The National Emergency Management Agency issues a tsunami advisory for all coastal areas in New Zealand following a 8.8 magnitude earthquake off the eastern coast of Kamchatka Peninsula. Gloriavale's Overseeing Shepherd Howard Temple pleads guilty to 12 charges including indecent assault, indecency and common assault. 31 July: Stuff shuts down 15 community newspapers including the Western Leader and The Hutt News. Dunedin-based media company Allied Press rebrands as Allied Media. The New Zealand Parliament passes legislation repealing a 2018 law limiting new oil and gas exploration permits off the coast of Taranaki. Director of the Federal Bureau of Investigation Kash Patel opens a new FBI attaché office in Wellington to boost bilateral law enforcement cooperation between the United States and New Zealand. Te Pāti Māori (Māori Party) files urgent High Court proceedings calling on the Electoral Commission, Ministry of Justice and the Ombudsman to investigate allegations that Māori voters had been removed from the Māori electoral roll without their consent. The Government introduces a law limiting voter enrolment before elections, banning prisoner voting, and starting voting 12 days early, amid rights concerns and opposition criticism.
Sources: en.wikipedia.org
== Select publications == Meindl, Kathrin; Schmiederer, Timo; Schneider, Kathrin; Reicke, Andreas; Butz, Diane; Keller, Simone; et al. (February 2010). "Labyrinthopeptine – eine neue Klasse carbacyclischer Lantibiotika". Angewandte Chemie (in German). 122 (6): 1169–1173. doi:10.1002/ange.200905773. Schadt, Heiko S.; Schadt, Simone; Oldach, Florian; Süssmuth, Roderich D. (February 18, 2009). "2-Amino-2-deoxyisochorismate Is a Key Intermediate in Bacillus subtilis p-Aminobenzoic Acid Biosynthesis". Journal of the American Chemical Society. 131 (10). doi:10.1021/ja809283u. Dettner, Frank; Hänchen, Anne; Schols, Dominique; Toti, Luigi; Nußer, Antje; Süssmuth, Roderich D. (February 2009). "Totalsynthese des antiviralen Peptidantibiotikums Feglymycin". Angewandte Chemie (in German). 121 (10): 1888–1893. doi:10.1002/ange.200804130. Bister, Bojan; Bischoff, Daniel; Ströbele, Markus; Riedlinger, Julia; Reicke, Andreas; Wolter, Falko; et al. (May 2004). "Abyssomicin C—A Polycyclic Antibiotic from a Marine Verrucosispora Strain as an Inhibitor of the p ‐Aminobenzoic Acid/Tetrahydrofolate Biosynthesis Pathway". Angewandte Chemie International Edition. 43 (19): 2574–2576. doi:10.1002/anie.200353160. Bister, Bojan; Bischoff, Daniel; Nicholson, Graeme J.; Valdebenito, Marianne; Schneider, Kathrin; Winkelmann, Günther; et al. (August 2004). "The structure of salmochelins: C-glucosylated enterobactins of Salmonella enterica §". Biometals. 17 (4): 471–481. doi:10.1023/B:BIOM.0000029432.69418.6a.
==== Hong Kong ==== In Hong Kong, codeine is regulated under the Laws of the Hong Kong, Dangerous Drugs Ordinance, Chapter 134, Schedule 1. It can be used legally only by health professionals and for university research purposes. The substance can be given by pharmacists under a prescription. Anyone who supplies the substance without a prescription can be fined $10,000 (HKD). The maximum penalty for trafficking or manufacturing the substance is a $5,000,000 (HKD) fine and life imprisonment. Possession of the substance for consumption without license from the Department of Health is illegal with a $1,000,000 (HKD) fine and/or 7 years of jail time. However, codeine is available without prescription from licensed pharmacists in doses up to 0.1% (i.e. 5 mg/5ml)
Dibenzoylmorphine is an opioid analogue that is a derivative of morphine. It was developed in the early 1900s after first having been synthesised in 1875 in the UK by the CR Alders Wright organisation at Bayer, along with various other esters of morphine. It was never used medically, instead being widely sold as one of the first "designer drugs" for around five years following the introduction of the first international restrictions on the sale of heroin in 1925. It is described as being virtually identical to heroin and morphine in its effects, and consequently was itself banned internationally in 1930 by the Health Committee of the League of Nations, in order to prevent its sale as an unscheduled alternative to diacetylmorphine. However, it still continues to occasionally be encountered as a result of home manufacture from morphine by drug users. It is produced in the same fashion as other esters of morphine—treating morphine with an acid anhydride (or some acids or other relatives of acids like acetyl chloride) to get a mono-, di-, tri-, or tetra-ester. Specifically, the original 1875 synthesis was effected by boiling morphine for 2 hours in benzoic anhydride at 130 °C, as was heroin made by using acetic anhydride.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.